Paolo Fusar-Poli1, Evangelos Papanastasiou2, Daniel Stahl3, Matteo Rocchetti4, William Carpenter5, Sukhwinder Shergill6, Philip McGuire1. 1. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK; OASIS team, South London and the Maudsley NHS Foundation Trust, London, UK; 2. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK; evangelos.e.papanastasiou@kcl.ac.uk. 3. Department of Biostatistics, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK; 4. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 5. Department of Psychiatry and Pharmacology, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD. 6. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK;
Abstract
OBJECTIVES: Existing treatments for schizophrenia can improve positive symptoms, but it is unclear if they have any impact on negative symptoms. This meta-analysis was conducted to assess the efficacy of available treatments for negative symptoms in schizophrenia. METHODS: All randomized-controlled trials of interventions for negative symptoms in schizophrenia until December 2013 were retrieved; 168 unique and independent placebo-controlled trials were used. Negative symptom scores at baseline and follow-up, duration of illness, doses of medication, type of interventions, and sample demographics were extracted. Heterogeneity was addressed with the I (2) and Q statistic. Standardized mean difference in values of the Negative Symptom Rating Scale used in each study was calculated as the main outcome measure. RESULTS: 6503 patients in the treatment arm and 5815 patients in the placebo arm were included. No evidence of publication biases found. Most treatments reduced negative symptoms at follow-up relative to placebo: second-generation antipsychotics: -0.579 (-0.755 to -0.404); antidepressants: -0.349 (-0.551 to -0.146); combinations of pharmacological agents: -0.518 (-0.757 to -0.279); glutamatergic medications: -0.289 (-0.478 to -0.1); psychological interventions: -0.396 (-0.563 to -0.229). No significant effect was found for first-generation antipsychotics: -0.531 (-1.104 to 0.041) and brain stimulation: -0.228 (-0.775 to 0.319). Effects of most treatments were not clinically meaningful as measured on Clinical Global Impression Severity Scale. CONCLUSIONS AND RELEVANCE: Although some statistically significant effects on negative symptoms were evident, none reached the threshold for clinically significant improvement.
OBJECTIVES: Existing treatments for schizophrenia can improve positive symptoms, but it is unclear if they have any impact on negative symptoms. This meta-analysis was conducted to assess the efficacy of available treatments for negative symptoms in schizophrenia. METHODS: All randomized-controlled trials of interventions for negative symptoms in schizophrenia until December 2013 were retrieved; 168 unique and independent placebo-controlled trials were used. Negative symptom scores at baseline and follow-up, duration of illness, doses of medication, type of interventions, and sample demographics were extracted. Heterogeneity was addressed with the I (2) and Q statistic. Standardized mean difference in values of the Negative Symptom Rating Scale used in each study was calculated as the main outcome measure. RESULTS: 6503 patients in the treatment arm and 5815 patients in the placebo arm were included. No evidence of publication biases found. Most treatments reduced negative symptoms at follow-up relative to placebo: second-generation antipsychotics: -0.579 (-0.755 to -0.404); antidepressants: -0.349 (-0.551 to -0.146); combinations of pharmacological agents: -0.518 (-0.757 to -0.279); glutamatergic medications: -0.289 (-0.478 to -0.1); psychological interventions: -0.396 (-0.563 to -0.229). No significant effect was found for first-generation antipsychotics: -0.531 (-1.104 to 0.041) and brain stimulation: -0.228 (-0.775 to 0.319). Effects of most treatments were not clinically meaningful as measured on Clinical Global Impression Severity Scale. CONCLUSIONS AND RELEVANCE: Although some statistically significant effects on negative symptoms were evident, none reached the threshold for clinically significant improvement.
Authors: L Magliano; G Fadden; M Madianos; J M de Almeida; T Held; M Guarneri; C Marasco; P Tosini; M Maj Journal: Soc Psychiatry Psychiatr Epidemiol Date: 1998-09 Impact factor: 4.328
Authors: L Magliano; G Fadden; M Economou; T Held; M Xavier; M Guarneri; C Malangone; C Marasco; M Maj Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2000-03 Impact factor: 4.328
Authors: P Lepping; C Schönfeldt-Lecuona; R S Sambhi; S V N Lanka; S Lane; R Whittington; S Leucht; R Poole Journal: Acta Psychiatr Scand Date: 2014-04-12 Impact factor: 6.392
Authors: Gregory P Strauss; Andrea Pelletier-Baldelli; Katherine Frost Visser; Elaine F Walker; Vijay A Mittal Journal: Schizophr Res Date: 2020-06-07 Impact factor: 4.939
Authors: Cathy Davies; Andrea Cipriani; John P A Ioannidis; Joaquim Radua; Daniel Stahl; Umberto Provenzani; Philip McGuire; Paolo Fusar-Poli Journal: World Psychiatry Date: 2018-06 Impact factor: 49.548
Authors: Thomas Bailey; Mario Alvarez-Jimenez; Ana M Garcia-Sanchez; Carol Hulbert; Emma Barlow; Sarah Bendall Journal: Schizophr Bull Date: 2018-08-20 Impact factor: 9.306
Authors: Ji Chen; Veronika I Müller; Juergen Dukart; Felix Hoffstaedter; Justin T Baker; Avram J Holmes; Deniz Vatansever; Thomas Nickl-Jockschat; Xiaojin Liu; Birgit Derntl; Lydia Kogler; Renaud Jardri; Oliver Gruber; André Aleman; Iris E Sommer; Simon B Eickhoff; Kaustubh R Patil Journal: Biol Psychiatry Date: 2020-10-03 Impact factor: 13.382
Authors: Gregory Paul Strauss; Farnaz Zamani Esfahlani; Brian Kirkpatrick; Daniel N Allen; James M Gold; Katherine Frost Visser; Hiroki Sayama Journal: Schizophr Bull Date: 2019-10-24 Impact factor: 9.306